

GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş.

Material Event Disclosure (General)

Summary

Signing of an Agreement with Republic of Türkiye Social Security Institution

Material Event Disclosure General

Related Companies []

Related Funds []

Material Event Disclosure General	
Update Notification Flag	Hayır (No)
Correction Notification Flag	Evet (Yes)
Date Of The Previous Notification About The Same Subject	17.01.2022
Postponed Notification Flag	Hayır (No)
Announcement Content	
Explanations	

-Unofficial Translation-

Republic of Türkiye Social Security Institution ("SGK/SSI") and Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. ("GEN") signed on 14.01.2022 an agreement concerning supply by GEN of a drug with active substance "Nusinersen Sodium" used for treatment of SMA disease ("the Agreement"). GEN, holding the leading position in our country in the field of drugs used in the treatment of rare diseases and in the therapy of functional disorders developing due to these diseases, strengthened this position with the Agreement.

The Agreement will be effective from 01.02.2022 and covers the period between 01.02.2022 and 01.03.2023. The contribution of the Agreement to GEN's sales in 2022 is expected to be between 950.000.000,00 TL (Nine hundred fifty million Turkish Liras) - 1.100.000.000,00 TL (One billion hundred million Turkish Liras) with the current exchange rates.

We proclaim that our above disclosure is in conformity with the principles set down in "Material Events Communiqué" of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we're personally liable for the disclosures.